Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...
In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...
Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported ...
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in phase II kidney trial: Ingelheim, Germany Thursday, January 29, 2026, 10:00 Hrs [IST] Bo ...
Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...
Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...
Dr. James McCaffrey presents a complete end-to-end demonstration of linear regression with pseudo-inverse training implemented using JavaScript. Compared to other training techniques, such as ...
Advances in structure-activity relationship studies, computational modeling, and rational combination strategies are accelerating progress toward clinical development. Inconsistencies in clinical ...
Dell's Alienware Area-51 laptop redefines high-performance computing, boasting an Intel Core Ultra 9 and RTX 5090 for ...
Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...
The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results